Larissa Warneck-Silvestrin

About

Science journalist at Labiotech.eu. Born half Kiwi, half German. I have a BSc in Biology and an MSc in Science Communication from different Universities. I love writing, painting and eating chocolate. Sometimes, I share.

Articles by Larissa Warneck-Silvestrin

Basel, Switzerland, city, biotech ecosystem

Basel: It Takes an Ecosystem to Build a Startup

Europe has a number of bubbling biotech hubs that offer access to expertise, financial support, and networking opportunities for young healthcare ventures. One of them is the Basel Area in Switzerland. It goes without saying that the basis of each biotech should always be world-class innovation. But that is just the beginning: In order to […]

March 7, 2023 - 8 minutesmins - By Larissa Warneck-Silvestrin

Best in Biotech 20 Dec 2021

The Billion-Euro European Biotech Companies in 2022

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]

December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin

Switzerland, Swiss biotech, Biotech Companies, startups

Best in Biotech 9 Jun 2021

Top 15 Swiss biotech startups making a difference in Europe

Switzerland has long been known as a booming biotech hotspot in Europe that boasts many high-profile companies. Here are the top 15 biotech companies among the new generation of promising startups in Switzerland. Last year saw a record-breaking amount of money pouring into the Swiss biotech industry. According to a recent report by the Swiss […]

June 9, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin

Interview 31 May 2021

What’s Ahead for European Biotech Startups After Covid?

With a tumultuous year behind us, 2021 is set out to spell change for many startups in the European biotech ecosystem. Following the Covid-19 pandemic and Brexit, the European biotech startup landscape has seen some big changes over the course of the past year. Jason Mellad and Dan Rooke, CEO and COO of the Cambridge-based […]

May 31, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 10 May 2021

The Rollercoaster of Repurposing an Arthritis Drug for Covid-19

The Covid-19 pandemic created an opportunity for many biotech companies to repurpose their existing programs into vaccines and treatments for the novel coronavirus. Cyxone’s CEO Tara Heitner and COO Malin Berthold discuss how they approached this shift at their company. Cyxone was founded in 2015 to develop drugs for rheumatoid arthritis and multiple sclerosis. Based […]

May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 5 Apr 2021

Base Editing: The Next Frontier in Genome Editing Technology

Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights into the promises of base editing technology. In less than a decade, the advent of CRISPR-Cas9 has made gene editing easier and faster than ever. But CRISPR, as well as earlier genome editing tools, have a series of technical limitations, […]

April 5, 2021 - 4 minutesmins - By Larissa Warneck-Silvestrin

Interview 15 Mar 2021

Developing a Vaccine that Protects Against Covid-19 Variants

Despite the promise of several approved Covid-19 vaccines and the widespread rollout of vaccination programs around the world, recent mutations in the virus causing Covid-19 are raising concern. Can the current vaccines protect against different coronavirus variants? Paul Higham became CEO of the Finnish firm Valo Therapeutics in 2020. The company was founded in 2016 […]

March 15, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Interview 3 Mar 2021

The Promises of CRISPR Genome Editing in Biomedicine

Tony Ho, Head of Research and Development at CRISPR Therapeutics, offers his insights into the advantages of CRISPR gene editing over other technologies and what the future holds for the genome editing field. For decades, gene editing required engineering DNA-cutting enzymes, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), for every specific […]

March 3, 2021 - 5 minutesmins - By Larissa Warneck-Silvestrin

Best in Biotech 25 Jan 2021

The 15 Best Biotech Companies in Belgium

Meet the most successful biotech companies in Belgium, a small country that makes a huge contribution to the biotech industry. With over 140 operating biotech companies and a solid network of renowned universities and research institutes, the Belgium biotech industry is a flourishing ecosystem. Despite its small size, Belgium represents nearly a quarter of the […]

January 25, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

Best in Biotech 11 Jan 2021

The 21 European Biotech Companies To Watch in 2021

As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year. There were many memorable moments for the European biotech industry in 2020. The Covid-19 pandemic took over the media and many […]

January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin

Reports 11 Nov 2020

Navigating the Immunotherapy Maze

Today, the global immunotherapy drugs market is valued at €139B ($163B) and is estimated to reach a staggering value of €149.3B ($174.6B) by 2025. Without a doubt, it is a flourishing field with new research emerging as you read. Discover now how antibodies, T cells, and exosomes are changing the immunotherapy field! While antibodies have […]

November 11, 2020 - 2 minutesmins - By Larissa Warneck-Silvestrin

Interview 28 Oct 2020

Do Natural Killer Cells Hold the Key to Treating Blood Cancers?

Novel immunotherapies, like T cell therapy, may have shown recent successes but they also come with a number of setbacks, such as long timelines and serious adverse reactions. As CEO of the Dutch biotech Kiadis Pharma, Arthur Lahr has been leading the development of a technology that could overcome these limitations by using natural killer […]

October 28, 2020 - 7 minutesmins - By Larissa Warneck-Silvestrin

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us